Robert Eisenbach

Of Counsel
Full contact info

For 30+ years I have been focused on getting results for clients by keeping an eye on the big picture, offering expertise and good judgment and keeping a cool head.

Experience

Foreseen Biotechnology Announces Exclusive Global Licensing Agreement With Ipsen

July 11, 2024

Cooley advised Foreseen Biotechnology – an emerging biotech company that pioneered a high-throughput integrated translational proteomics platform powered by an artificial intelligence-based data analytical system to accelerate the discovery of novel targets for therapeutics and diagnostics that are clinically relevant – on its exclusive global licensing agreement with Ipsen for FS001, an antibody-drug conjugate with first-in-class potential.

Read more

Related contacts

Lila Hope
Partner, Palo Alto
Jennifer Raab
Partner, Palo Alto
Jiqiang Lin
Associate, New York
Robert Eisenbach
Of Counsel, San Francisco
Amanda Pacheco
Associate, Palo Alto
Xander Lee
Partner, Santa Monica
David Burns
Special Counsel, Washington, DC

Related Practices & Industries

PhaseBio Chapter 11 Wind-Down Plan Goes Effective

June 26, 2024

The Chapter 11 plan of PhaseBio Pharmaceuticals, a long-standing Cooley life sciences client, has gone effective following the court’s confirmation of the Chapter 11 plan on June 26, 2024. The plan provides for a global settlement with the official committee of unsecured creditors and a settlement with PhaseBio’s former co-development partner. The Chapter 11 bankruptcy case in the US Bankruptcy Court for the District of Delaware was handled by a multioffice, cross-disciplinary Cooley team.

Related contacts

Jeremiah P. Ledwidge
Associate, New York
Robert Eisenbach
Of Counsel, San Francisco
Olya Antle
Associate, Washington, DC
Cullen Drescher Speckhart
Partner in Charge – Washington, DC, Washington, DC
Philip Bowman
Partner, New York
Victoria R. Pasculli
Associate, New York
Daniel Lockaby
Associate, New York
Dannielle Antone
Associate, San Francisco
Aaron Binstock
Partner, Washington, DC
Amanda Lindner
Associate, New York
Madison Jones
Partner, Washington, DC
Timothy Shapiro
Partner, Palo Alto
Grigor Lynch
Associate, Colorado
Christian Plaza
Partner, Reston
Joe Sandys
Associate, London
Aaron Pomeroy
Partner, Colorado
David Brinton
Associate, Washington, DC
Paul Springer
Associate, New York
Erika Freeman
Associate, New York
Michael Klein
Partner, New York
Daniel Knauss
Partner, Palo Alto
Pengli Li
Associate, Boston
Marya Postner
Partner, Palo Alto
Leo Metz
Associate
Michael Tuscan
Partner, Washington, DC
Allison Wettstein O’Neill
Associate, San Diego

Related Practices & Industries

Brii Biosciences Announces Agreements to Acquire VBI Vaccines’ IP Rights in BRII-179

February 14, 2024

Cooley advised Brii Biosciences on its agreements with VBI Vaccines (NASDAQ: VBIV) to ensure expansion and control of future clinical and commercial supplies of BRII-179, a late-stage clinical asset in Brii Bio’s hepatitis B virus functional cure portfolio. With operations in major biotechnology centers in the US and China, Brii Bio (HKSE: 2137) is a Hong Kong Stock Exchange-listed biotechnology company developing therapies to improve patient health and choice across diseases with high unmet needs.

Read more

Related contacts

Yiming Liu
Partner in Charge – Shanghai, Shanghai
Rama Padmanabhan
Partner, San Diego
Rajdeep Roger Bains
Associate, San Diego
Jason Savich
Partner, San Francisco
Lila Hope
Partner, Palo Alto
Michael Klein
Partner, New York
Michelle Garcia Schulman
Partner, Reston
Matthew S. Scarano
Associate, San Diego
Jameson Davis
Associate, Boston
Kaiting Yang
Associate, Hong Kong
Ross Eberly
Partner, Santa Monica
Jeffrey J. Tolin
Partner, New York
Michael Yu
Partner in Charge – Hong Kong, Hong Kong
Robert Eisenbach
Of Counsel, San Francisco
Rena Kaminsky
Special Counsel, Palo Alto
Olya Antle
Associate, Washington, DC
Adrienne Beaudoin Deshmukh
Associate, Reston
Yoni Horn
Associate, Santa Monica
Lunga Su
Associate, Shanghai
Yiying Wang
Associate, Shanghai

Related Practices & Industries

Blue Owl Capital Invests up to $1.05 Billion in BridgeBio Pharma

January 17, 2024

Cooley advised Blue Owl Capital, a top asset manager redefining alternatives, on its strategic investment a $300 million royalty financing and a $450 million credit facility in BridgeBio Pharma, a commercial-stage biopharmaceutical company focused on genetic diseases and cancers.

Read more

Related contacts

Mischi a Marca
Partner, San Francisco
Michael Tollini
Partner, Washington, DC
Addison Pierce
Associate, Chicago
Matt Kong
Associate, San Francisco
Xander Lee
Partner, Santa Monica
Geoffrey Spolyar
Partner, Boston
Jon Cousin
Partner, Washington, DC
Steve Flores
Partner, Chicago
Phil Mitchell
Partner, New York
Michael Egan
Partner, Washington, DC
Jeffrey J. Tolin
Partner, New York
Michael Klein
Partner, New York
Natasha Leskovsek
Of Counsel, Washington, DC
Robert Eisenbach
Of Counsel, San Francisco
Susan Piascik Christoff
Special Counsel, Washington, DC
Karen Tsai
Special Counsel, Washington, DC
Cathy Hershcopf
Senior Counsel, New York
Stevie Yu
Associate, New York
Yichao Zhang
Associate, New York
Rodrigo Huerta
Associate, Chicago
Jackson Alldredge
Associate, Colorado
Amanda Pacheco
Associate, Palo Alto
Celine Koh
Associate, Palo Alto
Jameson Davis
Associate, Boston
Allison Kutner
Associate, New York
Matthew S. Scarano
Associate, San Diego
Xueqing Li
Associate, San Francisco
Mor Agam
Associate, New York
Miriam Peguero Medrano
Associate, Chicago
Sam Rabuck
Associate, Chicago
Chris Rhem
Paralegal Specialist, San Francisco
Veronica Cortes
Paralegal Specialist, New York
Jennifer Fitzpatrick
Paralegal Specialist, Washington, DC
Jason Minio
Paralegal Specialist, Boston
Jeffery Wyzykowski
Patent Agent, Washington, DC

Related Practices & Industries

Allorion Therapeutics Announces Exclusive Option, Global License Agreement With AstraZeneca

January 2, 2024

Cooley advised Allorion Therapeutics, a US- and China-based biotechnology company that focuses on the discovery of new small molecule drugs for treating cancer and autoimmune diseases, on its exclusive option and global license agreement with AstraZeneca to develop and commercialize a novel epidermal growth factor receptor (EGFR) L858R mutated allosteric inhibitor as a potential new treatment for advanced EGFR-mutant non-small-cell lung cancer.

Read more

Related contacts

Marya Postner
Partner, Palo Alto
Brendan Haberle
Associate, San Diego
Yiming Liu
Partner in Charge – Shanghai, Shanghai
Jameson Davis
Associate, Boston
Xander Lee
Partner, Santa Monica
Mor Agam
Associate, New York
Sharon Connaughton
Special Counsel, Washington, DC
Rachel Thorn
Partner, New York
Natasha Leskovsek
Of Counsel, Washington, DC
Jessica Koffel
Associate, Brussels
Robert Eisenbach
Of Counsel, San Francisco

Related Practices & Industries

View more

Admissions and credentials

California

Rankings and accolades

Northern California Super Lawyers

Best Lawyers in America

Memberships and affiliations

American Bankruptcy Institute, member

American Bar Association (ABA)

Bay Area Bankruptcy Forum

Turnaround Management Association

The best in the business

Legal 500 US